In the current investigation, the primary protein targets of berberine in AD therapy were identified as EGFR and BCL2, both of which play essential roles in neuroinflammation and apoptosis, aligning with the proposed mechanism of action. This evidence concerns the gene EGFR and Alzheimer disease.